Skip to content
LATEST
Health

Vitamin B12 Identified as Potential Therapeutic for Rare Genetic Splicing Disorders

Vitamin B12 has been shown to reverse developmental defects in laboratory models of Verheij syndrome, suggesting a potential new metabolic-based treatment…

Vitamin B12 Identified as Potential Therapeutic for Rare Genetic Splicing Disorders

Researchers have identified that vitamin B12 supplementation can reverse developmental abnormalities in laboratory models of Verheij syndrome, a rare genetic disorder characterized by growth impairment and developmental delays. The study indicates that mutations associated with the syndrome disrupt RNA splicing, which subsequently impairs vitamin B12-dependent metabolic pathways.

Experiments conducted on C. elegans demonstrated that the administration of vitamin B12 restored normal metabolic function and corrected growth defects caused by the genetic mutation. This suggests that the underlying pathology of certain spliceosomopathies may be rooted in metabolic disruption rather than solely in protein synthesis errors.

Clinical investigations involving human blood samples confirmed that Clinical investigations involving human blood samples confirmed that patients with Verheij syndrome exhibit metabolic markers similar to those observed in the laboratory models. These findings suggest that the metabolic pathways identified in the study are conserved across species and may be relevant to human disease progression.

While the results provide a potential mechanism for While the results provide a potential mechanism for therapeutic intervention, clinical efficacy in humans remains unproven. Further research is required to determine if vitamin B12 supplementation can safely and effectively mitigate symptoms in patients diagnosed with the disorder.

The study highlights a broader potential for identifying metabolic vulnerabilities in rare genetic diseases caused by RNA splicing defects. This approach may facilitate the development of new treatment strategies for a range of conditions currently lacking targeted pharmacological interventions.

More stories

Latest news